These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 31737965)

  • 41. Harm reduction: come as you are.
    Marlatt GA
    Addict Behav; 1996; 21(6):779-88. PubMed ID: 8904943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The trajectory of methadone maintenance treatment in Nepal.
    Ambekar A; Rao R; Pun A; Kumar S; Kishore K
    Int J Drug Policy; 2013 Nov; 24(6):e57-60. PubMed ID: 23845916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The value of harm reduction for injection drug use: A clinical and public health ethics analysis.
    Vearrier L
    Dis Mon; 2019 May; 65(5):119-141. PubMed ID: 30600096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Society for the Study of Addiction (SSA).
    Tober G
    Addiction; 2004 Jun; 99(6):677-85. PubMed ID: 15139866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran.
    Nikfarjam A; Shokoohi M; Shahesmaeili A; Haghdoost AA; Baneshi MR; Haji-Maghsoudi S; Rastegari A; Nasehi AA; Memaryan N; Tarjoman T
    Int J Drug Policy; 2016 May; 31():147-52. PubMed ID: 26980349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of an Innovative Voluntary Substance Abuse Treatment Program Designed to Replace Compulsory Drug Detention Centers in Malaysia.
    Khan F; Krishnan A; Ghani MA; Wickersham JA; Fu JJ; Lim SH; Dhaliwal SK; Kamarulzaman A; Altice FL
    Subst Use Misuse; 2018 Jan; 53(2):249-259. PubMed ID: 28635521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Double counting of clients using services in Iran: implications for assessing the reach of harm reduction programs.
    Tavakoli F; Mcfarland W; Ghalekhani N; Khezri M; Haghdoost AA; Gouya MM; Mahboobi M; Hosseionpour AM; Komasi A; Ghorbanian M; Nasiri Moghadam N; Taghipour M; Sharifi H
    Harm Reduct J; 2023 Aug; 20(1):111. PubMed ID: 37587473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Canadian harm reduction policies: A comparative content analysis of provincial and territorial documents, 2000-2015.
    Wild TC; Pauly B; Belle-Isle L; Cavalieri W; Elliott R; Strike C; Tupper K; Hathaway A; Dell C; MacPherson D; Sinclair C; Karekezi K; Tan B; Hyshka E
    Int J Drug Policy; 2017 Jul; 45():9-17. PubMed ID: 28454045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The network of Centres for the Prevention and Treatment of Drug Addiction in the Republic of Slovenia.
    Kastelic A; Rihtar TK
    Med Arh; 2001; 55(3):135-9. PubMed ID: 11769426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Compulsory drug treatment in Canada: historical origins and recent developments.
    Fischer B; Roberts JV; Kirst M
    Eur Addict Res; 2002 Apr; 8(2):61-8. PubMed ID: 11979008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV risk behavior among injection drug users in Tehran, Iran.
    Razani N; Mohraz M; Kheirandish P; Malekinejad M; Malekafzali H; Mokri A; McFarland W; Rutherford G
    Addiction; 2007 Sep; 102(9):1472-82. PubMed ID: 17645427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new direction in population policy and family planning in the Islamic Republic of Iran.
    Aghajanian A
    Asia Pac Popul J; 1995 Mar; 10(1):3-20. PubMed ID: 12319483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Needle and Syringe Programs and HIV-Related Risk Behaviors Among Men Who Inject Drugs: A Multilevel Analysis of Two Cities in Iran.
    Noroozi M; Noroozi A; Sharifi H; Harouni GG; Marshall BDL; Ghisvand H; Qorbani M; Armoon B
    Int J Behav Med; 2019 Feb; 26(1):50-58. PubMed ID: 30460445
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The making of the chronic addict.
    Järvinen M; Andersen D
    Subst Use Misuse; 2009; 44(6):865-85. PubMed ID: 19444727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs.
    Des Jarlais DC; Paone D; Friedman SR; Peyser N; Newman RG
    Am J Public Health; 1995 Nov; 85(11):1577-84. PubMed ID: 7485676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The issue of harm reduction in Polish legislation concerning drug addiction. A comparative study].
    Sobeyko J
    Ann Acad Med Stetin; 2008; 54(2):119-31. PubMed ID: 19374242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Introduction: the three phases of harm reduction. An examination of emerging concepts, methodologies, and critiques.
    Erickson PG
    Subst Use Misuse; 1999 Jan; 34(1):1-7. PubMed ID: 10052386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. From addiction to infection: managing drug abuse in the context of HIV/AIDS in Africa.
    Akindipe T; Abiodun L; Adebajo S; Lawal R; Rataemane S
    Afr J Reprod Health; 2014 Sep; 18(3 Spec No):47-54. PubMed ID: 26050376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Addiction Research Centres and the Nurturing of Creativity. Substance abuse research in a modern health care centre: the case of the Centre for Addiction and Mental Health.
    Rehm J; Giesbrecht N; Gliksman L; Graham K; Le AD; Mann RE; Room R; Rush B; Tyndale RF; Wells S
    Addiction; 2011 Apr; 106(4):689-97. PubMed ID: 20491727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.